DAC 0060

Drug Profile

DAC 0060

Alternative Names: DAC-0060; DAC-060; DAC60

Latest Information Update: 12 Feb 2016

Price : $50

At a glance

  • Originator DAC Research
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer

Most Recent Events

  • 12 Feb 2016 Phase-II development for Basal cell cancer is ongoing in Italy
  • 30 Oct 2013 Phase-II clinical trials in Basal cell cancer (Combination therapy) in Italy (Topical)
  • 14 Oct 2010 DAC 0060 is available for out-licensing (http://www.genextra.it/partnering.html)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top